Health Care & Life Sciences » Biotechnology | Galectin Therapeutics Inc.

Galectin Therapeutics Inc.

Galectin Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
37.74 M
Public Float
31.89 M
Galectin Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.32
Market Cap
$221.76 M
Shares Outstanding
56 M
Public Float
34.4 M

Profile

Address
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
United States
Employees -
Website http://www.galectintherapeutics.com
Updated 07/08/2019
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C.

Financials

View All
Created with Highcharts 5.0.14Galectin Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.21 08021 08016 01716 01720 02720 02721 43621 43616 23516 23513 90013 90020132014201520162017201805k10k15k20k25k

Richard E. Uihlein
Chairman
Marc Rubin
Director